Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

May 13, 2024•over 1 year ago

Amount Raised

$95 Million

Round Type

series c

New YorkBiotechnology

Investors

Inning One VenturesSchrödinger, Inc.Boxer CapitalEco R1 CapitalPoint72Ra Capital ManagementVivo CapitalEli Lilly And CompanyGoldman Sachs Alternatives

Description

Ajax Therapeutics, Inc. announced the closing of an oversubscribed $95 million Series C financing. The proceeds will be used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs.

Company Information

Company

Ajax Therapeutics, Inc.

Location

275 MADISON AVE, 39TH FLOOR

New York, New York, United States

About

Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel next generation therapies for myeloproliferative neoplasms (MPNs), including myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends